Exploring Strategic Insights into the Commercial Strategy Implications of the Inflation Reduction Act for Cell & Gene Therapy Administration to Ensure Strategic Advantages for Future Development Initiatives
Time: 9:01 am
day: Pre-Conference Workshop Day
Details:
Cell and gene therapies have some of the highest manufacturer prices in the US and so are an obvious target for negotiation. Therefore, the CMS is proceeding with implementing the provisions of the 2022 IRA. This legislation is expected to set upper limits on the negotiated price between manufacturers and US government-funded drug plans for high-budget impact drugs. So, how is this expected to affect the cell and gene therapy landscape?
Join to:
- Delve into the implications of the CMMI’s “Cell and Gene Therapy Access Model,” assessing whether drugs fall within the provisions of the Inflation Reduction Act (IRA), providing clarity on regulatory impacts
- Understand the commercial strategy implications of the Inflation Reduction Act (IRA) concerning the administration of cell and gene therapies in hospital and outpatient settings, enabling informed decision-making in different healthcare environments
- Explore strategic pathways by focusing on the development of cell and gene therapies within orphan indications with prevalent conditions, aiming to avoid or delay the impact of the Inflation Reduction Act (IRA) in the future
